Home            Past Issues            About IP            About IAP           Author Information            Subscription            Advertisement              Search  

   
CLINICAL CASE letter

Indian Pediatr 2020;57: 753-754

Novel Coronavirus Mimicking Kawasaki Disease in an Infant

 

Bhaswati C Acharyya1*, Saumyabrata Acharyya2 and Dhritabrata Das3

Departments of 1Pediatric Gastroenterology, 2Pediatrics, and 3Pediatric Cardiology, AMRI Hospitals, Kolkata, West Bengal, India.
Email: [email protected]

Published online: May 22, 2020;
PII:
S097475592000659

 


C
oronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uncommonly causes severe disease in children [1]. Over the last two months; however, a new hyper inflammatory condition manifesting as Kawasaki disease or Kawasaki-like shock syndrome has been described in children above 4 years of age, across Europe and USA [2-4], with increased risk of mortality. One case from India has also been reported [5]. Here we report an infant presenting with fever and clinical manifestations of Kawasaki disease and subsequently screening positive for COVID-19.

A 4-month-old healthy baby, weighing 5.6 kg, and born to non-consanguineous parents, presented with high-grade fever for 4 days. Fever was spiking 6-8 hourly reaching 39 0C. He developed an erythematous macular rash over the trunk, palm and sole on second day. On admission the child was hemodynamically stable and was breastfeeding normally. He was very irritable with red lips, congested throat and small cervical lymphadenopathy without any cough or nasal congestion. He had clear chest, normal regular heart sounds and a saturation of 97-98% in air. Investigations revealed a hemoglobin of 9.9 g/dL, total leucocyte count of 14770/mm3 with 50% neutrophils, platelet count 4.25×109/L, C-reactive protein (CRP) of 115.6 mg/L, normal liver enzymes with albumin 30 g/L and globulin of 22 g/L, and a normal chest X-ray. His nasopharyngeal swab was sent for SARS-CoV-2 RT-PCR and other viral PCR tests. Treatment was started with meropenem and vancomycin after sending blood and urine culture, but fever continued till the third day of admission, when he developed non-purulent conjunctivitis with left subconjunctival hemorrhage. Repeat CRP showed a higher value of 178.2 mg/L. With evolving clinical signs simulating Kawasaki disease, an echocardiography was performed. It showed normal left ventricular function, perivascular brightness and diffuse ectasia of coronary arteries with left middle coronary artery (LMCA) of 2.7 mm (Z score +2.6) (Fig. 1a), left anterior descending artery of 2 mm (Z score +2.9) and proximal right coronary artery (RCA) of 2.4 mm (Z score +3.6) (Fig. 1b). Oral aspirin (80 mg/kg) and intravenous immune-globulin (IVIG) (2 g/kg) therapy was started. He stayed stable clinically and did not need intensive care. Fever subsided after 24 hours of finishing IVIG infusion, and the child became playful. Subsequently, SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) showed a positive result and he was shifted to a COVID-designated hospital. All cultures were negative till 7 days. Repeat blood test revealed a downward trend of CRP (148 mg/L). Swab for other viruses was negative. To date the baby is stable, afebrile, and is kept under observation in the pediatric ward. His mother was also subsequently found positive for SARS-CoV-2.


(a)

(b)

Fig. 1 Ectasia of (a) left main coronary artery (LMCA) and (b) right coronary artery (RCA).

Children of all ages can acquire COVID-19, although they appear to be affected less commonly than adults [1,6,7]. The most common symptoms in pediatric SARS-CoV2 infection are fever and cough [1,6]. This infant also presented with fever but his extreme irritability was unusual. In a previous series, approximately 11% of infants had severe or critical disease [1]. This infant was never critical throughout the period of hospitalization.

During this pandemic, Jones, et al. [2] published the first case of a 6-month-old female admitted and diagnosed with classic Kawasaki disease, which tested positive for COVID-19. This was followed by more similar reports of children with COVID-19 and clinical features that are similar to those of toxic shock syndrome and atypical Kawasaki disease and laboratory findings associated with increased inflammation [3-5]. Royal College of Paediatrics and Child Health (RCPCH) labeled this new inflammatory entity as Paediatric multisystem inflam-matory syndrome temporally associated with COVID-19 [8]. Case definitions include persistent fever, inflammation and evidence of single or multi-organ dysfunction after exclusion of other microbial causes. The case mentioned showed a rise of CRP without any neutrophilia, lymphopenia or organ dysfunction.

Our case was very similar to that described by Jones, et al. [2] but that girl had persistent tachycardia and most of the clinical features of KD with normal echocardiography. Riphagen, et al. [3] reported a case series of 8 children (only 3 tested COVID-19 positive) needing intensive care support with a hyper-inflammatory shock. One child died after a massive cerebral infarction. All of them had features mentioned in RCPCH guidelines with minimal respiratory symptoms [3]. These children and the two infants with Kawasaki disease most likely had a similar pathogenesis with varied consequences, which needs further research to define it.

India is still in the early stage of this pandemic and has not yet had many children with severe COVID-19. This 4-month-old child presenting as typical Kawasaki disease represents a novel presentation among the very young population with COVID-19.

REFERENCES

1. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of covid-19 among children in China. Pediatrics. 2020; 145. Available from: www. aappublications.org/news. Accessed May 10, 2020.

2. Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Segal JB, et al. COVID-19 and Kawasaki disease: Novel virus and novel case. Hosp Pediatr. 2020. Available from: https://hosppeds.aappublications.org/content/hosppeds/early/2020/04/06/ hpeds.2020-0123.full.pdf. Assessed May 10 2020.

3. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020 (Epub ahead of print). Available from: https://www.thelancet.com/journals/ lancet/article/PIIS0140-6736(20)31094-1/fulltext. Accessed May 11, 2020.

4. Rivera-Figueroa A, Santos R, Simpson S, Garg P. Incomplete Kawasaki disease in a child with Covid-19. Indian Pediatr. 2020 May 9 [Epub ahead of print]. Available from: https:// www.indianpediatrics.net/COVID29.03.2020/CCL-00179. pdf. Accessed May 21, 2020.

5. Balasubramanian S, Nagendran TM, Ramachandran B, Ramanan AV. Hyper-inflammatory syndrome in a child with COVID-19 treated successfully with intravenous immunoglobulin and tocilizumab. Indian Pediatr. 2020 May 10 [Epub ahead of print]. Available from: https:// www.indianpediatrics.net/COVID29.03.2020/CCL-00180. pdf. Accessed May 21, 2020.

6. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:422 6.

7. Balasubramanian S, Rao NM, Goenka A, Roderick M, Ramanan AV. Coronavirus disease (covid-19) in children - What we know so far and what we do not. Indian Pediatr. 2020 Apr 9 [Epub ahead of print]. Available from: https://www.indianpediatrics.net/COVID29.03.2020/SA-00159. pdf. Accessed May 09, 2020.

8. Royal College of Paediatrics and Child Health. COVID-19 guidance for pediatric services. Available from: https://www.rcpch.ac.uk/resources/guidance-paediatricmulti systeminflammatory-syndrome-temporally-associated covid19. Accessed May 11, 2020.


 

Copyright © 1999-2020 Indian Pediatrics